FHIR CI-Build

This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions

Example ClinicalUseDefinition/example-indication (Turtle)

Biomedical Research and Regulation Work GroupMaturity Level: N/AStandards Status: InformativeCompartments: No defined compartments

Raw Turtle (+ also see Turtle/RDF Format Specification)

Indication example

@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

[a fhir:ClinicalUseDefinition ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "example-indication"] ; # 
  fhir:text [
     fhir:status [ fhir:v "extensions" ] ;
     fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: ClinicalUseDefinition</b><a name=\"example-indication\"> </a><a name=\"hcexample-indication\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ClinicalUseDefinition &quot;example-indication&quot; </p></div><p><b>StructureDefinition Work Group</b>: brr</p><p><b>type</b>: indication</p><p><b>subject</b>: <a href=\"medicinalproductdefinition-example.html\">MedicinalProductDefinition/example</a></p><blockquote><p><b>indication</b></p><h3>DiseaseSymptomProcedures</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (indicationasdisease-symptom-procedure#Pulmonary-embolism-and-thrombosis-example-code)</span></td></tr></table><h3>DiseaseStatuses</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Recurrent <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (diseasestatus#Recurrent)</span></td></tr></table><h3>IntendedEffects</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>PRYLX <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (intendedeffect#PRYLX)</span></td></tr></table></blockquote><p><b>population</b>: <a name=\"hcgroup\"> </a></p><blockquote><p/><p><a name=\"group\"> </a></p><p><a name=\"hcgroup\"> </a></p><p><b>type</b>: person</p><p><b>membership</b>: definitional</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td>age-range <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (characteristic#age-range)</span></td><td>18-? a</td><td>false</td></tr></table></blockquote><hr/><blockquote><p><b>Generated Narrative: Group #group</b><a name=\"group\"> </a><a name=\"hcgroup\"> </a></p><p><b>type</b>: person</p><p><b>membership</b>: definitional</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td>age-range <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (characteristic#age-range)</span></td><td>18-? a</td><td>false</td></tr></table></blockquote></div>"
  ] ; #    example product is indicated for Prevention of venous thromboembolic events, in adults (18+)   ,    product is for 18 years and above   
  fhir:contained ( [
     a fhir:Group ;
     fhir:id [ fhir:v "group" ] ;
     fhir:type [ fhir:v "person" ] ;
     fhir:membership [ fhir:v "definitional" ] ;
     fhir:characteristic ( [
       fhir:code [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/characteristic"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "age-range" ]
         ] )
       ] ;
       fhir:value [
         a fhir:Range ;
         fhir:low [
           fhir:value [ fhir:v "18"^^xsd:decimal ] ;
           fhir:unit [ fhir:v "a" ]
         ]
       ] ;
       fhir:exclude [ fhir:v "false"^^xsd:boolean ]
     ] )
  ] ) ; # 
  fhir:extension ( [
     fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"^^xsd:anyURI ] ;
     fhir:value [ fhir:v "brr" ]
  ] ) ; # 
  fhir:type [ fhir:v "indication"] ; # 
  fhir:subject ( [
     fhir:reference [ fhir:v "MedicinalProductDefinition/example" ]
  ] ) ; # 
  fhir:indication [
     fhir:diseaseSymptomProcedure [
       fhir:concept [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/indicationasdisease-symptom-procedure"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "Pulmonary-embolism-and-thrombosis-example-code" ]
         ] ) ;
         fhir:text [ fhir:v "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults." ]
       ]
     ] ;
     fhir:diseaseStatus [
       fhir:concept [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/diseasestatus"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "Recurrent" ]
         ] )
       ]
     ] ;
     fhir:intendedEffect [
       fhir:concept [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/intendedeffect"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "PRYLX" ]
         ] )
       ]
     ]
  ] ; #    example product is indicated for Prevention of venous thromboembolic events   
  fhir:population ( [
     fhir:reference [ fhir:v "#group" ]
  ] )] . # 

# -------------------------------------------------------------------------------------


Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.